Congress Stops NIH From Implementing New Clinical Trials Policy

The US Congress has directed the National Institutes of Health (NIH) to “delay enforcement” of a new policy that would reclassify basic research involving humans as “clinical trials.” Lawmakers concluded that the research community was not adequately consulted about this change and that the policy could have “long-term unintended consequences,” including unnecessary regulations and the inappropriate inclusion of nonclinical trials in NIH’s database.

APS has been a leading voice in opposing NIH’s redefinition of clinical trials, which would have brought basic behavioral and neuroscience research under the umbrella of clinical trials and would have subjected those areas to unwarranted, costly, and time-consuming administrative requirements.

Although the general outline of the new clinical trials policy had been proposed for some time, basic researchers were unaware of it until June 2017, when NIH developed its operational definition of clinical trials as “a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.”

This definition, “coupled with the requirement that applications be submitted under a clinical trial-specific funding opportunity announcement … will certainly have a negative impact on basic behavioral science,” wrote Sarah Brookhart, APS Executive Director, in a June 6, 2017 letter to NIH Director Francis Collins. “The undue burden placed on researchers, institutions, and NIH in terms of the application process, conduct of research, and monitoring requirements is enormous.”

Wider opposition to the new clinical trials definition was slow to build, in part due to the arcane nature of the issue. It really boiled down to a few words in a larger set of rule changes. Further, basic researchers initially didn’t focus on the problem because something labeled “clinical trials” simply would not have been on their radar. That was the Catch-22 aspect of this issue. However, once the research community became aware of the issue there was unprecedented opposition, including a petition signed by more than 3,500 researchers, including many leaders of APS.

Opposition mounted throughout the summer of 2017. There was even news coverage of the community’s concerns in Science. Unfortunately, in its responses to APS and others, NIH dismissed the community’s concerns as unwarranted and too late — the policy would go into effect as planned, they said.

In early September 2017, APS first alerted Congress to the deleterious impact of NIH’s redefinition of clinical trials, telling members of the House and Senate appropriations committees that “NIH has expanded its definition of clinical trials in order to increase participation of federal grantees in, a registry for presenting the findings of clinical studies. While this is intended to meet the laudable goal of increased transparency, this change will have a serious and negative impact on basic science and significantly increase the regulatory burden on Universities and researchers. There are other less disruptive ways to meet the goal of increased transparency.”

In providing additional background, Brookhart indicated that “the inappropriate classification of basic science as clinical trials has the potential to set back scientific discovery because of its impact on individual investigations, on research institutions, and on NIH itself.”

“We are asking that NIH (1) set aside its new definition of ‘clinical trial,’ and (2) work with the scientific community to develop a means for allowing public access to research findings from basic studies without insisting the research be labeled as clinical trials,” she added. “This would in no way prevent NIH from moving forward with efforts to increase participation by true clinical trials in and it will avoid the serious problems that we have outlined.”

Fortunately, APS’s message resonated with Congress, which has instructed NIH not to enforce the new policy except for studies that were clinical trials under the prior definition, and has told NIH to consult with the affected areas of science and to report back to Congress. These directives were conveyed as part of the Omnibus budget that the House and Senate passed March 22. President Trump signed the bill.

Excerpt from the Joint Explanatory Statement to the Consolidated Appropriation Act, 2018 (a.k.a. the Omnibus Agreement), section on the National Institutes of Health:

Clinical Trials Definition: The agreement appreciates efforts NIH has taken to increase transparency and improve oversight of its clinical trials and recognizes that the results of NIH-funded clinical trials have not always been reported in a timely manner, reducing the potential benefit from the findings. The agreement urges NIH to continue to address this problem through enhanced registration and reporting through There is concern, however, that in addressing this issue, many fundamental research studies involving human participants are being redefined as clinical trials without sufficient notification and consultation with this segment of the research community. Fundamental research is critical to the NIH mission and of value to the public, and there is concern that policy changes could have long-term, unintended consequences for this research, add unnecessary regulatory burdens, and substantially increase the number of studies in the database that are not clinical trials. For fiscal year 2018, the agreement directs NIH to delay enforcement of the new policy published in the Federal Register on September 21, 2017 including NIH’s more expansive interpretation of “interventions”-in relation to fundamental research projects involving humans. [emphasis added] The new policy should go forward for research projects that would have been considered clinical trials under the prior policy. This delay is intended to provide NIH sufficient time to consult with the basic research community to determine the reporting standards best suited to this kind of research. The agreement directs NIH to provide the Committees on Appropriations of the House of Representatives and the Senate a plan and schedule for soliciting comments and input from the research community within 30 days of enactment of this act, and brief the Committees on the results of these consultations and next steps by June 22, 2018.

Congress is very supportive of NIH as the world’s preeminent health research agency, just as APS is a loyal constituent of NIH and works to strengthen support for its budget. However, as seen by the report language above, Congressional appropriators also recognized the community’s concerns that there was a disconnect between the stated objectives of the proposed clinical trials policy and the move to include basic research under that policy. NIH still has not provided sufficient rationale for a change that had potential for such far-reaching negative consequences. However, APS will continue to work with NIH and Congress on this issue to help develop solutions that address NIH’s objectives while advancing basic behavioral research relating to NIH’s public health research mission.

Additional Background:

NIH redefines clinical trials, attracting critics, Science, July 21, 2017.

Scientists hate the NIH’s new rules for experimenting on humans, Wired, January 26, 2018.

Leave a Comment

Your email address will not be published.
In the interest of transparency, we do not accept anonymous comments.
Required fields are marked*